Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-01
2011-03-01
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S312700, C548S311100
Reexamination Certificate
active
07897632
ABSTRACT:
The present invention provides a compound represented by the formula (I):or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
REFERENCES:
patent: 3470167 (1969-09-01), Sarkar
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 4910200 (1990-03-01), Curtze et al.
patent: 5281626 (1994-01-01), Oinuma et al.
patent: 5563162 (1996-10-01), Oku et al.
patent: 5804577 (1998-09-01), Hebeisen et al.
patent: 5985856 (1999-11-01), Stella et al.
patent: 6235728 (2001-05-01), Golik et al.
patent: 6306870 (2001-10-01), Bombrun
patent: 7053087 (2006-05-01), Beatch et al.
patent: 7138414 (2006-11-01), Schoenafinger et al.
patent: 7300936 (2007-11-01), Parker et al.
patent: 7314940 (2008-01-01), Graczyk et al.
patent: 7618960 (2009-11-01), Kimura et al.
patent: 7667041 (2010-02-01), Kimura et al.
patent: 2001/0051642 (2001-12-01), Ahn et al.
patent: 2002/0128263 (2002-09-01), Mutel et al.
patent: 2002/0183324 (2002-12-01), Jacobson et al.
patent: 2003/0195201 (2003-10-01), Bo et al.
patent: 2003/0208082 (2003-11-01), Mutel et al.
patent: 2003/0225070 (2003-12-01), Mutel et al.
patent: 2004/0006062 (2004-01-01), Smallheer et al.
patent: 2004/0034096 (2004-02-01), Jolidon et al.
patent: 2004/0038969 (2004-02-01), Doherty et al.
patent: 2004/0063770 (2004-04-01), Ahn et al.
patent: 2004/0087798 (2004-05-01), Yamada
patent: 2004/0127494 (2004-07-01), Parker et al.
patent: 2004/0127555 (2004-07-01), Snow et al.
patent: 2004/0152743 (2004-08-01), Schoenafinger et al.
patent: 2004/0192743 (2004-09-01), Mjalli et al.
patent: 2004/0235864 (2004-11-01), Graczyk et al.
patent: 2005/0070538 (2005-03-01), Cheng et al.
patent: 2005/0131043 (2005-06-01), Mutel et al.
patent: 2005/0187277 (2005-08-01), Mjalli et al.
patent: 2006/0004013 (2006-01-01), Kimura et al.
patent: 2007/0117798 (2007-05-01), Kimura et al.
patent: 2007/0117839 (2007-05-01), Kimura et al.
patent: 2007/0219181 (2007-09-01), Kimura et al.
patent: 2007/0249833 (2007-10-01), Cheng et al.
patent: 2008/0070902 (2008-03-01), Kimura et al.
patent: 2008/0085894 (2008-04-01), Parker et al.
patent: 2008/0096892 (2008-04-01), Cheng et al.
patent: 2008/0280948 (2008-11-01), Baumann et al.
patent: 2009/0048213 (2009-02-01), Kimura et al.
patent: 2009/0048448 (2009-02-01), Kushida et al.
patent: 2009/0203916 (2009-08-01), Kushida et al.
patent: 2009/0270623 (2009-10-01), Shimomura et al.
patent: 3541716 (1987-05-01), None
patent: 0 219 756 (1987-04-01), None
patent: 1 264 820 (2002-12-01), None
patent: 0 973 768 (2003-07-01), None
patent: 1 757 591 (2007-02-01), None
patent: 1 808 432 (2007-07-01), None
patent: 1 953 151 (2008-08-01), None
patent: 1 953 158 (2008-08-01), None
patent: P 2006 3920 (2006-09-01), None
patent: P 2008 4571 (2008-12-01), None
patent: 52-1035 (1977-01-01), None
patent: 3-206042 (1991-09-01), None
patent: 7-2780 (1995-01-01), None
patent: 8-283219 (1996-10-01), None
patent: 9-132578 (1997-05-01), None
patent: 10-510512 (1998-10-01), None
patent: 11-228548 (1999-08-01), None
patent: 11-513686 (1999-11-01), None
patent: 3176365 (2001-04-01), None
patent: 2001-508767 (2001-07-01), None
patent: 2001-527083 (2001-12-01), None
patent: 2003-206280 (2003-07-01), None
patent: 2004-520292 (2004-07-01), None
patent: 2004-531519 (2004-10-01), None
patent: 2004-536084 (2004-12-01), None
patent: 2005-518371 (2005-06-01), None
patent: 2005-526807 (2005-09-01), None
patent: 2005-531596 (2005-10-01), None
patent: 2005-533092 (2005-11-01), None
patent: 2006-502247 (2006-01-01), None
patent: 2006-518738 (2006-08-01), None
patent: 2007-504282 (2007-03-01), None
patent: 2007-523903 (2007-08-01), None
patent: 2001126135 (2003-07-01), None
patent: 91/12237 (1991-08-01), None
patent: 95/21832 (1995-08-01), None
patent: 96/10559 (1996-04-01), None
patent: 97/14417 (1997-04-01), None
patent: 97/43287 (1997-11-01), None
patent: 98/03166 (1998-01-01), None
patent: 98/09963 (1998-03-01), None
patent: 98/24785 (1998-06-01), None
patent: WO 99/55693 (1999-11-01), None
patent: 00/07993 (2000-02-01), None
patent: 00/50391 (2000-08-01), None
patent: 00/51981 (2000-09-01), None
patent: 01/68585 (2001-09-01), None
patent: 01/81312 (2001-11-01), None
patent: 03/027081 (2003-04-01), None
patent: 03/053912 (2003-07-01), None
patent: 03/074497 (2003-09-01), None
patent: 03/082292 (2003-10-01), None
patent: 03/101927 (2003-12-01), None
patent: 2004/002478 (2004-01-01), None
patent: 2004/007429 (2004-01-01), None
patent: 2004/007455 (2004-01-01), None
patent: 2004/041776 (2004-05-01), None
patent: 2004/089868 (2004-10-01), None
patent: 2005/020921 (2005-03-01), None
patent: 2005/063754 (2005-07-01), None
patent: 2005/072731 (2005-08-01), None
patent: 2005/087767 (2005-09-01), None
patent: 2005/115990 (2005-12-01), None
patent: 2006/046575 (2006-05-01), None
patent: 2006/112550 (2006-10-01), None
patent: 2007/034282 (2007-03-01), None
patent: 2007/060810 (2007-05-01), None
patent: 2007/102580 (2007-09-01), None
patent: 2008/013213 (2008-01-01), None
patent: 2008/097538 (2008-08-01), None
patent: 2008/137139 (2008-11-01), None
patent: 2008/156580 (2008-12-01), None
patent: 2009/020580 (2009-02-01), None
Eurasian Office Action issued Mar. 12, 2010, in Eurasian Application No. 200870336/28.
Ross et al., “Antiparasitic Nitroimidazoles.3.Synthesis of 2-(4-carboxystyryl)-5-nitro-1-vinylimidazole and Related Compounds”, J. of Medicinal Chemistry, vol. 16, No. 4, 1973, pp. 347-352.
Assini et al., “Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment, Neurology,” vol. 63, pp. 828-831, Sep. 2004.
Atwood et al., “Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply,” Brain Research Reviews, vol. 43, pp. 164-178, 2003.
Barelli et al., “Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid β Peptides . . . ,” Molecular Medicine, vol. 3, No. 10, pp. 695-707, Oct. 1997.
Barrachina et al., “Amyloid-β deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AβPP mRNA isoforms containing the Kunitz protease inhibitor,” Neurochemistry International, vol. 46, pp. 253-260, 2005.
Blass, “Brain Metabolism and Brain Disease: Is Metabolic Deficiency the Proximate Cause of Alzheimer Dementia?,” Journal of Neuroscience Research, vol. 66, pp. 851-856, 2001.
Brocchini et al., “Preparation of piperazinedione-derivative inhibitors of plasminogen activator inhibitor,” Database CA [Online] Chemical Abstracts Service, XP002574973, retrieved from STN, Database accession No. 1995:994197, Abstract, (1995).
Calhoun et al., “Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid,” Proceedings of the National Academy of Sciences, vol. 96, No. 24, pp. 14088-14093, Nov. 23, 1999.
Catalano et al., “The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimer's Disease,” Current Topics in Medicinal Chemistry, vol. 6, pp. 597-608, 2006.
Chen et al., “Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution,” International Journal of Pharmaceutics, vol. 242, pp. 3-14, 2002.
Comery et al., “Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease,” The Journal of Neuroscience, vol. 25, No. 39, pp. 8898-8902, Sep. 28, 2005.
Comery et al., “Acutey-secretase inhibition improves cognition in the TG2576 mouse model of Alzheime
Doi Eriko
Doko Takashi
Hagiwara Hiroaki
Ito Koichi
Kaneko Toshihiko
Birch & Stewart Kolasch & Birch, LLP
EISAI R&D Management Co., Ltd.
Habte Kahsay T
LandOfFree
Multi-cyclic cinnamide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multi-cyclic cinnamide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-cyclic cinnamide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663724